PubMed for id: 8763

Year	Number of Results
1992	1
1996	1
1998	2
1999	1
2000	2
2001	2
2002	1
2003	1
2005	2
2006	3
2007	2
2008	4
2009	2
2010	2
2011	2
2012	1
2013	4
2014	4
2015	2
2016	3
2017	2
2018	1
2019	1
2020	5
2022	3
2024	0

1

Genome-Wide Knockout Screen Identifies Human Sialomucin CD164 as an Essential Entry Factor for Lymphocytic Choriomeningitis Virus.

Liu J, Knopp KA, Rackaityte E, Wang CY, Laurie MT, Sunshine S, Puschnik AS, DeRisi JL. Liu J, et al. mBio. 2022 Jun 28;13(3):e0020522. doi: 10.1128/mbio.00205-22. Epub 2022 May 3. mBio. 2022. PMID: 35502904 Free PMC article.

2

CD164 is a host factor for lymphocytic choriomeningitis virus entry.

Bakkers MJG, Moon-Walker A, Herlo R, Brusic V, Stubbs SH, Hastie KM, Saphire EO, Kirchhausen TL, Whelan SPJ. Bakkers MJG, et al. Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2119676119. doi: 10.1073/pnas.2119676119. Epub 2022 Mar 2. Proc Natl Acad Sci U S A. 2022. PMID: 35235462 Free PMC article.

3

CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer.

Zhang XG, Zhang T, Li CY, Zhang MH, Chen FM. Zhang XG, et al. Cancer Med. 2018 Aug;7(8):3763-3772. doi: 10.1002/cam4.1607. Epub 2018 Jul 18. Cancer Med. 2018. PMID: 30022623 Free PMC article.

4

MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer.

Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji L. Lin J, et al. J Gene Ther. 2016 Feb;2(1):6. doi: 10.13188/2381-3326.1000006. Epub 2016 Feb 13. J Gene Ther. 2016. PMID: 27376157 Free PMC article.

5

Expression of CD164 on Malignant T cells in Sézary Syndrome.

Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini AA, Mitev V, Dummer R, Kazakov DV, French LE, Hoetzenecker W, Cozzio A. Guenova E, et al. Acta Derm Venereol. 2016 May;96(4):464-7. doi: 10.2340/00015555-2264. Acta Derm Venereol. 2016. PMID: 26524186 Free article.

6

CD164 and FCRL3 are highly expressed on CD4+CD26- T cells in Sézary syndrome patients.

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH. Wysocka M, et al. J Invest Dermatol. 2014 Jan;134(1):229-236. doi: 10.1038/jid.2013.279. Epub 2013 Jun 21. J Invest Dermatol. 2014. PMID: 23792457 Free PMC article.

7

Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo.

Tang J, Zhang L, She X, Zhou G, Yu F, Xiang J, Li G. Tang J, et al. Cancer Invest. 2012 Jun;30(5):380-9. doi: 10.3109/07357907.2012.666692. Epub 2012 Mar 12. Cancer Invest. 2012. PMID: 22409183

8

Cis-regulatory functions of overlapping HIF-1alpha/E-box/AP-1-like sequences of CD164.

Tang J, Luo Z, Zhou G, Song C, Yu F, Xiang J, Li G. Tang J, et al. BMC Mol Biol. 2011 Oct 14;12:44. doi: 10.1186/1471-2199-12-44. BMC Mol Biol. 2011. PMID: 21999799 Free PMC article.

9

Validation of basophil CD164 upregulation for pollen allergy diagnosis.

Wolanczyk-Medrala A, Barg W, Liebhart J, Panaszek B, Nadobna G, Litwa M, Gogolewski G, Medrala W. Wolanczyk-Medrala A, et al. Arch Immunol Ther Exp (Warsz). 2010 Dec;58(6):459-65. doi: 10.1007/s00005-010-0104-z. Epub 2010 Sep 28. Arch Immunol Ther Exp (Warsz). 2010. PMID: 20872290 Free article.

10

The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis.

Havens AM, Jung Y, Sun YX, Wang J, Shah RB, Bühring HJ, Pienta KJ, Taichman RS. Havens AM, et al. BMC Cancer. 2006 Jul 21;6:195. doi: 10.1186/1471-2407-6-195. BMC Cancer. 2006. PMID: 16859559 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

49 results

Results by year